Analysis multivariate of survival and prognostic factors in a cohort of patients with hormone receptor-positive breast cancer.

Análisis multivariado de la supervivencia y los factores pronósticos de una cohorte de paciente con cáncer de mama receptor hormonal positivo.

Objective: The main purpose of this investigation was to evaluate prognosis factors associated with the overall and desease free survival of hormone receptor-positive breast cancer. Methods: The data for this investigation was collected from the hospital Oncocare, from patients that were diagnosed with hormone receptor-positive breast cancer (stage I to IIIC) during the period of January 1st, 2003 to July 31st, 2012. This information was first used to construct survival curves using the Kaplan-Meier methods, then compared by using range logarithms, they were analysed using proportional range of regression by Cox. Results: In this investigation, a total of 387 patients were used, the mortality rate for the cohort was 7.24%, and relapses were 9.82%. The median age was 55.3 years old, and the median follow-up were 48.2 months. The clinical stage distribution were as it follows, stage I 10.85%, IIA 16.28%, IIB 17.05%, IIIA 22.74%, IIIB 19.12% and IIIC 13.95%; the HER2 receptors are positive by 13.7%. The percentage of patients that received neoadjuvant chemotherapy was 60.72%; 59.15% were type AC and 22.25% were type ACT. Additionally, 73.90% received adjuvant chemotherapy: type AC 44.91%, trastuzumab 14.7% and taxenes 23.25%. The response to neoadjuvant chemotherapy were: objective response 76.17%, complete 14.89%, partial 61.28 %; relapse were 9.82% (local 2.58%, regionals 1.29% and systematic 7.75%). Multivariate analysis also suggests that the number of positive lymph nodes, 10 or more, decrease desease free survival HR 2.30 (1.39-2.80). The clinical objective response, the tumour size, HER2 positive, positive hormonal receptors, age and clinical stage do not affect overall and desease free survival in the multivariate analysis. Conclusion: The desease free survival decreases with 10 or more positive lymph nodes. Other variables such as tumour size, clinical stage, age, HER2 positive and objective clinical response do not affect overall and desease free survival.